Schrödinger Inc. - SDGR Market Capitalization

Schrodinger, Inc. (SDGR) is betting on the synergy between IT solutions and scientific partnerships with industry behemoths, replacing mergers with joint drug development in exchange for a percentage of sales. The price action of SDGR securities, where market capitalization reaches 2.03, reflects the business dynamics. The company generates revenue from SaaS subscriptions and AI-driven molecular design, while also advancing its own clinical trials and the deep integration of software into drug discovery.

SDGR schrodinger.com: Market Value in the range 07/04/2022 - 11/13/2026

Analytical breakdowns for Schrodinger Corp (SDGR)

- current price and projected stock value:

Stock Price Schrödinger|SDGR - Broker Consensus Forecast

- issuer market value details:

Market Capitalization Schrodinger Corp|SDGR - Full Takeover Company Value

- issuer book value statistics:

Net Assets per Single Share Schrödinger|SDGR - Accounting Value of Company|Market Capitalization to Book Value Ratio schrodinger.com|SDGR - Company Total Asset Base

- debt and liquidity details:

- business earnings and investment ratios data:

SDGR - Company Profit|Expected Profit Schrodinger, Inc.|SDGR - Business Payback Period|Forward P/E Multiple Schrödinger Inc.|SDGR - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Schrodinger Corp|SDGR - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Schrödinger|SDGR - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months schrodinger.com|SDGR - Earnings per share growth rate in current year|Earnings growth forecast for next year Schrodinger, Inc.

Summary company analysis:SDGR (Schrödinger)

Manufactured products of schrodinger.com

The market capitalization of Schrodinger, Inc. (SDGR) reflects the aggregate value of all shares, which, given the dependence on R&D cycles within the biotech sector, serves as an indicator of market confidence in future royalties. By analyzing the issuer's total market capitalization, an investor assesses the product of the current share price and the number of outstanding shares, allowing for a determination of the business's resilience to the risks associated with prolonged drug development.

Competitors of Schrodinger, Inc. (SDGR)